Atlas Trials

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

Clinical trial NCT05599932 · COMPLETED

Trial details

NCT number
NCT05599932
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic Impairment
Start date
2022-12-02
Primary completion
2023-09-18
Enrollment
38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.